domingo, 12 de abril de 2020

Guidance Documents | CDC

Guidance Documents | CDC
coronavirus

Guidance Documents



CDC’s gateway to interact with U.S. clinical laboratories. Currently, LOCS is a functional CDC mailbox designed to provide updates and answer questions from clinical laboratories through coordination with professional organizations, CDC programs, and state public health laboratories.
Date: 3/27/20
Audience: Laboratory
Guidance for the collection and submission of postmortem specimens from deceased persons under investigation (PUI) for COVID-19. Plus recommendations for biosafety and infection control practices during specimen collection and handling, including during autopsy procedures.
Date: 3/25/20
Guidance to be used by Alternative Care Sites caring for COVID 19 confirmed or suspected cases.
Date: 3/25/20
Audience:
Actions that persons and communities can take to help slow the spread of respiratory virus infections.
Date: 3/25/20
Guidance intended to support response planning by homeless service providers, including overnight emergency shelters, day shelters, and meal service providers.
Date: 3/24/20
Audience: Community Settings
Guidance to help community- and faith-based organizations (CFBOs) plan for community transmission of coronavirus disease 2019 (COVID-19)
Date: 3/23/20
Audience: Community Settings
Guidance for healthcare staff and public health officials regarding discontinuing transmission-based precautions and discharging hospitalized patients with COVID-19.
Date: 3/23/20
Guidance specific for correctional facilities and detention centers during the outbreak of COVID-19, to ensure continuation of essential public services and protection of the health and safety of incarcerated and detained persons, staff, and visitors.
Date: 3/23/20
This guidance is intended to provide key actions that local and state health departments, homelessness service systems, housing authorities, emergency planners, healthcare facilities, and homeless outreach services can take to protect people experiencing homelessness from the spread of COVID-19.
Date: 3/22/20
This document describes the procedures for completing the 2019 Novel Coronavirus (COVID-19) Person Under Investigation (PUI) and Case Report Form (CRF) for persons under investigation who are being tested or have been tested for the virus that causes COVID-19, and presumptive positive cases and confirmed cases of COVID-19.
Date: 3/21/20
Provides information on two of the approved drugs (chloroquine and hydroxychloroquine) and one of the investigational agents (remdesivir) currently in use in the United States.
Date: 3/21/20
Guidance for nursing homes and other long-term care facilities to take steps to assess and improve their preparedness for responding to coronavirus disease 2019 (COVID-19).
Date: 3/21/20
Audience:
To prevent further spread of SARS-CoV-2 and to collect information to better understand the virus and its impact on health outcomes, CDC is working with state and local health departments to identify persons under investigation (PUI) in the United States and test them for the virus that causes COVID-19.
Date: 3/21/20
This guidance is for administration, staff, and volunteers at blood and plasma collection facilities.
Date: 3/21/20
This guidance is for owners, administrators, operators, workers, volunteers, visitors, and residents of retirement communities and ILF that are not healthcare facilities.
Date: 3/20/20
Audience: Community Settings
Guidance for staff at local and state health departments, infection prevention and control professionals, and healthcare personnel who are coordinating the home care and isolation1 of people with confirmed or suspected COVID-19 infection, including persons under investigation.
Date: 3/20/20
Steps that healthcare facilities can take to prepare for an outbreak of coronavirus disease (COVID-19) among patients and staff.
Date: 3/20/20
Audience:
Guide to strategies for allocating stockpiled ventilators to healthcare systems and facilities during the COVID-19 response.
Date: 3/20/20
The Food and Drug Administration (FDA) issued new guidance that indicated laboratories could develop coronavirus disease 2019 (COVID-19) molecular diagnostics tests and begin to use them before obtaining Emergency Use Authorization (EUA).
Date: 3/20/20
Audience: Laboratory
The Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for the CDC 2(COVID-19) Real-Time RT-PCR Diagnostic Panel which is to be used in qualified laboratories for testing patient respiratory specimens that meet CDC criteria for COVID-19 testing.
Date: 3/20/20
Audience: Laboratory

No hay comentarios:

Publicar un comentario